The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GNPX | -94.95% | -99.93% | -76.84% | -100% |
| S&P | +13.66% | +87.02% | +13.34% | +153% |
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
No news articles found for Genprex.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Market Cap | $8.51M | 328.4% |
| Market Cap / Employee | $0.57M | 0.0% |
| Employees | 15 | 0.0% |
| Net Income | -$3.80M | 12.0% |
| EBITDA | -$3.35M | 22.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.10M | -25.9% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -448.99% | -228.0% |
| Return On Invested Capital | -386.77% | -190.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.19M | -45.8% |
| Operating Free Cash Flow | -$3.19M | -45.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.71 | 1.53 | 5.43 | 11.08 | 829.00% |
| Price to Tangible Book Value | 140.38 | 82.22 | 71.16 | 201.80 | 1797.25% |
| Enterprise Value to EBITDA | -1.76 | -0.07 | -1.06 | -1.60 | -3200.31% |
| Return on Equity | -467.2% | -302.7% | -602.6% | -1378.6% | 324.04% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
